Tianda Pharmaceuticals Limited is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The main businesses of the Company include the research and development, production and sales of pharmaceutical, biotechnology and healthcare products. Its products include cardio-cerebrovascular drugs, paediatric drugs, anti-flu and respiratory system drugs, anti-infection drugs, medicines for drug addicts and other pharmaceutical products, as well as healthcare products under the Herb Valley series. The Company operates businesses in Hong Kong, China and Australia.

Employees

613

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
26-04-13	0.0970 $	0.00%
26-04-10	0.0970 $	0.00%
26-04-09	0.0970 $	0.00%

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Delayed Hong Kong S.E. Other stock markets 04:08:48 2026-04-13 am EDT			5-day change	1st Jan Change
0.0970 ^HKD	0.00%		0.00%	-24.81%

Mar. 26	Tianda Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-28	Tianda Pharmaceuticals Limited Announces Resignation of Mr. Feng Quanming as a Non-Executive Director of the Company, Effective 29 August 2025	CI

Capitalization	277M 35.41M 30.25M 27.89M 26.32M 48.91M 3.32B 50.16M 327M 128M 1.58B 133M 130M 5.66B	P/E ratio 2023	-19.4x	P/E ratio 2024	-5.92x
Enterprise value	313M 39.96M 34.14M 31.47M 29.7M 55.19M 3.74B 56.6M 369M 145M 1.79B 150M 147M 6.38B	EV / Sales 2023	0.77x	EV / Sales 2024	1.21x
Free-Float	20.57%	Yield 2023	1.19%	Yield 2024	-

Mar. 26	Tianda Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-28	Tianda Pharmaceuticals Limited Announces Resignation of Mr. Feng Quanming as a Non-Executive Director of the Company, Effective 29 August 2025	CI
25-08-28	Tianda Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-06-27	Tianda Pharmaceuticals Limited Announces Board and Committee Changes, Effective June 27, 2025	CI
25-03-28	Tianda Pharmaceuticals Limited Recommends No Final Dividend for the Year Ended 31 December 2024	CI
25-03-28	Tianda Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-25	Tianda Pharmaceuticals Says Loss Attributable Expected To Increase To Hk$61 Million For FY	RE
25-03-25	Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2024	CI
24-08-28	Tianda Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-08-22	Tianda Pharmaceuticals Warns of Wider H1 Loss	MT
24-08-22	Tianda Pharmaceuticals Limited Provides Unaudited Consolidated Earnings Guidance for the Six-Month Period from 1 January 2024 to 30 June 2024	CI
24-06-11	Tianda Pharma Unit's Ibuprofen Gets Approval in China	MT
24-06-11	Tianda Pharmaceutical Technology Co., Ltd. Receives Drug Registration Approval of Ibuprofen Suspension	CI

22-11-25	Tianda Pharma Announces 2022/23 Interim Results	AQ
22-06-29	Tianda Pharmaceuticals Annual Results 2022	AQ
21-11-26	Tianda Pharma Interim Results 2021	AQ
21-08-25	Tianda Pharmaceuticals : POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 26 AUGUST 2021 AND RETIREMENT OF NON-EXECUTIVE DIRECTOR	PU
21-05-03	Tianda Pharmaceuticals : Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April, 2021	PU

Tianda Pharmaceuticals Limited Stock

Equities

455

KYG887471038

Pharmaceuticals

Valuation: Tianda Pharmaceuticals Limited

Chart: Tianda Pharmaceuticals Limited

Latest news: Tianda Pharmaceuticals Limited

Press Releases: Tianda Pharmaceuticals Limited

Quotes and Performance

Course Extremes

Managers and Directors: Tianda Pharmaceuticals Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	0.1	0.1
1 month	0.09	0.1
Current year	0.09	0.14
1 year	0.09	0.22
3 years	0.09	0.28
5 years	0.09	0.43
10 years	0.09	0.57

Manager	Title	Age	Since
Wen Quan Fang CEO	Chief Executive Officer	57	2009-12-13
Tai On Lo SEC	Corporate Secretary	71	-

Director	Title	Age	Since
Yat Fai Lam BRD	Director/Board Member	60	2003-12-31
Wen Quan Fang CHM	Chairman	57	2009-12-13
Sung Hong Chiu BRD	Director/Board Member	79	2008-04-09

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
TIANDA PHARMACEUTICALS LIMITED	0.00%	0.00%	-28.68%	-57.83%	26.63M
ELI LILLY AND COMPANY	-1.06%	+0.27%	+26.92%	+147.78%	832B
JOHNSON & JOHNSON	-0.21%	-1.25%	+56.83%	+43.25%	573B
ABBVIE INC.	-0.71%	-0.11%	+17.95%	+26.91%	365B
ROCHE HOLDING AG	-0.35%	-0.75%	+29.45%	+14.12%	322B
ASTRAZENECA PLC	-1.59%	-2.14%	+49.76%	+25.78%	313B
MERCK & CO., INC.	-1.05%	-0.58%	+51.74%	+3.95%	297B
NOVARTIS AG	-0.94%	-2.09%	+40.11%	+38.47%	292B
AMGEN INC.	-0.34%	+2.12%	+22.32%	+39.13%	189B
GILEAD SCIENCES, INC.	+0.03%	-0.78%	+34.16%	+66.96%	173B
Average	-0.51%	-0.58%	+30.06%	+34.85%	335.5B
Weighted average by Cap.	-0.47%	-0.65%	+36.88%	+60.06%

	2023	2024
Net sales	532M 67.93M 58.03M 53.51M 50.5M 93.84M 6.36B 96.22M 627M 246M 3.04B 255M 250M 10.85B	330M 42.12M 35.99M 33.18M 31.31M 58.19M 3.94B 59.66M 389M 153M 1.88B 158M 155M 6.73B
Net income	-24.16M -3.08M -2.63M -2.43M -2.29M -4.26M -289M -4.37M -28.45M -11.19M -138M -11.57M -11.33M -493M	-61.37M -7.84M -6.69M -6.17M -5.82M -10.82M -734M -11.1M -72.29M -28.42M -350M -29.41M -28.78M -1.25B
Net Debt	-57.28M -7.31M -6.25M -5.76M -5.44M -10.1M -685M -10.36M -67.47M -26.52M -327M -27.44M -26.86M -1.17B	35.61M 4.55M 3.88M 3.58M 3.38M 6.28M 426M 6.44M 41.95M 16.49M 203M 17.06M 16.7M 726M

3 months	-23.62%
6 months	-34.01%
Current year	-24.81%